Quest Diagnostics Inc has recently seen a notable shift in its shareholder structure, as State Street Corporation has reported acquiring over 5% of its common stock. This development, filed on November 10, 2026, is significant for both the company and the broader medical laboratory services industry.

Background

Quest Diagnostics Inc, a leading provider in the medical laboratory services sector, operates under the Standard Industrial Classification (SIC) code 8071. The company is listed on the New York Stock Exchange under the ticker symbol DGX. Recent filings show that Quest Diagnostics has been active in the market, with multiple forms submitted in November 2026, including a Form 4 and a Schedule 13G.

What the Filing Says

According to the Schedule 13G filing, State Street Corporation now holds a total of 5,563,421 shares of Quest Diagnostics, representing approximately 5% of the company's common stock. The filing indicates that State Street has shared voting power over 3,406,108 shares and shared dispositive power over 5,557,626 shares. This acquisition suggests a strategic interest in influencing the company's direction.

Impact

This investment by State Street Corporation may have various implications for Quest Diagnostics and its stakeholders, including shareholders and employees. With State Street's significant stake, there could be increased scrutiny on Quest's business strategies and operational performance. Additionally, this move may encourage other institutional investors to consider similar investments in the company.

What's Next

The filing does not say what happens next regarding this investment or any potential actions that State Street Corporation may take as a significant shareholder.